Mikihiko Naito

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 20

Top Topics

Chronic Myeloid Leukemia

Muscular Dystrophy

Top Venues

ACS medicinal chemistry letters

RSC medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Miyako Naganuma, Nobumichi Ohoka, Genichiro Tsuji, Takao Inoue, Mikihiko Naito, Yosuke Demizu
Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor. Bioconjugate chemistry (2023)
Po-Chang Shih, Miyako Naganuma, Yosuke Demizu, Mikihiko Naito
Current Status of Oligonucleotide-Based Protein Degraders. Pharmaceutics 15 (3) (2023)
Hidetomo Yokoo, Mikihiko Naito, Yosuke Demizu
Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs). Expert opinion on drug discovery (2023)
Po-Chang Shih, Miyako Naganuma, Yosuke Demizu, Mikihiko Naito
Current Status of Oligonucleotide-Based Protein Degraders. Pharmaceutics 15 (3) (2023)
Po-Chang Shih, Miyako Naganuma, Yosuke Demizu, Mikihiko Naito
Current Status of Oligonucleotide-Based Protein Degraders. Pharmaceutics 15 (3) (2023)
Haruna Tsujimura, Miyako Naganuma, Nobumichi Ohoka, Takao Inoue, Mikihiko Naito, Genichiro Tsuji, Yosuke Demizu
Development of DNA Aptamer-Based PROTACs That Degrade the Estrogen Receptor. ACS medicinal chemistry letters 14 (6) (2023)
Yuki Murakami, Hinata Osawa, Takashi Kurohara, Yuta Yanase, Takahito Ito, Hidetomo Yokoo, Norihito Shibata, Mikihiko Naito, Kosuke Aritake, Yosuke Demizu
Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D 2 synthase. RSC medicinal chemistry 13 (12) (2022)
Waka Sato, Mikihiko Naito
Inducing Protein Degradation to Overcome Resistance to Kinase Inhibitors. Biochemistry (2022)
Nobumichi Ohoka, Masanori Suzuki, Takuya Uchida, Genichiro Tsuji, Yoshinori Tsukumo, Masayuki Yoshida, Takao Inoue, Yosuke Demizu, Hitoshi Ohki, Mikihiko Naito
Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein. ACS medicinal chemistry letters 13 (12) (2022)
Nobumichi Ohoka, Masanori Suzuki, Takuya Uchida, Genichiro Tsuji, Yoshinori Tsukumo, Masayuki Yoshida, Takao Inoue, Yosuke Demizu, Hitoshi Ohki, Mikihiko Naito
Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein. ACS medicinal chemistry letters 13 (12) (2022)
Yuki Murakami, Hinata Osawa, Takashi Kurohara, Yuta Yanase, Takahito Ito, Hidetomo Yokoo, Norihito Shibata, Mikihiko Naito, Kosuke Aritake, Yosuke Demizu
Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D 2 synthase. RSC medicinal chemistry 13 (12) (2022)
Nobumichi Ohoka, Masanori Suzuki, Takuya Uchida, Yoshinori Tsukumo, Masayuki Yoshida, Takao Inoue, Hitoshi Ohki, Mikihiko Naito
Development of a potent small-molecule degrader against oncogenic BRAF V600E protein that evades paradoxical MAPK activation. Cancer science 113 (8) (2022)
Yoshino Akizuki, Mai Morita, Yuki Mori, Ai Kaiho-Soma, Shivani Dixit, Akinori Endo, Marie Shimogawa, Gosuke Hayashi, Mikihiko Naito, Akimitsu Okamoto, Keiji Tanaka, Yasushi Saeki, Fumiaki Ohtake
cIAP1-based degraders induce degradation via branched ubiquitin architectures. Nature chemical biology (2022)
Norihito Shibata, Nobumichi Ohoka, Genichiro Tsuji, Yosuke Demizu, Keiji Miyazawa, Kumiko Ui-Tei, Tetsu Akiyama, Mikihiko Naito
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells. Oncogene 39 (19) (2020)
Nobumichi Ohoka, Genichiro Tsuji, Takuji Shoda, Takuma Fujisato, Masaaki Kurihara, Yosuke Demizu, Mikihiko Naito
Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins. ACS chemical biology 14 (12) (2019)
Norihito Shibata, Kenichiro Shimokawa, Katsunori Nagai, Nobumichi Ohoka, Takayuki Hattori, Naoki Miyamoto, Osamu Ujikawa, Tomoya Sameshima, Hiroshi Nara, Nobuo Cho, Mikihiko Naito
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase. Scientific reports 8 (1) (2018)
Nobumichi Ohoka, Katsunori Nagai, Norihito Shibata, Takayuki Hattori, Hiroshi Nara, Nobuo Cho, Mikihiko Naito
SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib. Cancer science 108 (5) (2017)
Koyo Okitsu, Takayuki Hattori, Takashi Misawa, Takuji Shoda, Masaaki Kurihara, Mikihiko Naito, Yosuke Demizu
Development of a Small Hybrid Molecule That Mediates Degradation of His-Tag Fused Proteins. Journal of medicinal chemistry 61 (2) (2017)
Norihito Shibata, Naoki Miyamoto, Katsunori Nagai, Kenichiro Shimokawa, Tomoya Sameshima, Nobumichi Ohoka, Takayuki Hattori, Yasuhiro Imaeda, Hiroshi Nara, Nobuo Cho, Mikihiko Naito
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer science 108 (8) (2017)
Norihito Shibata, Katsunori Nagai, Yoko Morita, Osamu Ujikawa, Nobumichi Ohoka, Takayuki Hattori, Ryokichi Koyama, Osamu Sano, Yasuhiro Imaeda, Hiroshi Nara, Nobuo Cho, Mikihiko Naito
Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands. Journal of medicinal chemistry 61 (2) (2017)